Quick Summary:
The Global Glucagon-Like Peptide-1 Agonists Market is a sphere of pharmaceutical importance seeing considerable growth and development. These protein incretin mimetics play a crucial role in the management of Type 2 diabetes by influencing glucose regulation. This comprehensive report is indispensable for anyone aiming to gain an in-depth understanding of this evolving market.
The report will guide you through key insights from regional supply and demand dynamics to competitive landscapes, touching the Americas to Asia, Europe and the MEA region. It insightfully provides market size forecasts to guide your strategic planning. It also includes detailed profiles of key players in the market: Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb and Amylin. Each profile includes a SWOT analysis, sales volume, revenue, price, gross margin, and market share. From hospitals to pharmacies, this report will shape your understanding of this prominent segment, arming you with invaluable strategic insights.
For the geography segment, regional supply, demand, major players, price is presented from 2018 to 2028.
This report covers the following regions:
- North America
- South America
- Asia & Pacific
- Europe
- MEA
For the competitor segment, the report includes global key players of Glucagon like peptide-1 agonists as well as some small players.
The information for each competitor includes:
- Company Profile
- Main Business Information
- SWOT Analysis
- Sales Volume, Revenue, Price and Gross Margin
- Market Share
Applications Segment:
- Hospital
- Pharmacy
- Other
Types Segment:
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
Companies Covered:
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
Historical Data: from 2018 to 2022
Forecast Data: from 2023 to 2028
This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
Methodology
LOADING...